Head-To-Head Contrast: TNF Pharmaceuticals (TNFA) versus The Competition

Risk and Volatility

TNF Pharmaceuticals has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals’ rivals have a beta of 1.31, indicating that their average stock price is 31% more volatile than the S&P 500.

Institutional and Insider Ownership

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 1.2% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares TNF Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-180.71%	-84.27%
TNF Pharmaceuticals Competitors	-2,067.68%	-46.11%	-27.32%

Earnings and Valuation

This table compares TNF Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	-$4.00 million	-0.01
TNF Pharmaceuticals Competitors	$573.38 million	-$73.09 million	-96.37

TNF Pharmaceuticals’ rivals have higher revenue, but lower earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

TNF Pharmaceuticals rivals beat TNF Pharmaceuticals on 5 of the 9 factors compared.

TNF Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.